MISSISSIPPI LEGISLATURE

2024 Regular Session

To: Judiciary B

By: Representatives Owen, Ford (73rd)

House Bill 1342

AN ACT TO BRING FORWARD SECTION 41-29-139, MISSISSIPPI CODE OF 1972, WHICH PROVIDES PENALTIES FOR POSSESSION AND SALE OF UNLAWFUL DRUGS; TO BRING FORWARD SECTIONS 41-29-113, 41-29-115, 41-29-117, 41-29-119 AND 41-29-121, MISSISSIPPI CODE OF 1972, WHICH PROVIDE SCHEDULES ONE TO FIVE OF CONTROLLED SUBSTANCES FOR PURPOSES OF AMENDMENT; AND FOR RELATED PURPOSES.

     BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

     SECTION 1.  Section 41-29-139, Mississippi Code of 1972, is brought forward as follows:

     41-29-139.  (a)  Transfer and possession with intent to transfer.  Except as authorized by this article, it is unlawful for any person knowingly or intentionally:

          (1)  To sell, barter, transfer, manufacture, distribute, dispense or possess with intent to sell, barter, transfer, manufacture, distribute or dispense, a controlled substance; or

          (2)  To create, sell, barter, transfer, distribute, dispense or possess with intent to create, sell, barter, transfer, distribute or dispense, a counterfeit substance.

     (b)  Punishment for transfer and possession with intent to transfer.  Except as otherwise provided in Section 41-29-142, any person who violates subsection (a) of this section shall be, if convicted, sentenced as follows:

          (1)  For controlled substances classified in Schedule I or II, as set out in Sections 41-29-113 and 41-29-115, other than marijuana or synthetic cannabinoids:

              (A)  If less than two (2) grams or ten (10) dosage units, by imprisonment for not more than eight (8) years or a fine of not more than Fifty Thousand Dollars ($50,000.00), or both.

              (B)  If two (2) or more grams or ten (10) or more dosage units, but less than ten (10) grams or twenty (20) dosage units, by imprisonment for not less than three (3) years nor more than twenty (20) years or a fine of not more than Two Hundred Fifty Thousand Dollars ($250,000.00), or both.

              (C)  If ten (10) or more grams or twenty (20) or more dosage units, but less than thirty (30) grams or forty (40) dosage units, by imprisonment for not less than five (5) years nor more than thirty (30) years or a fine of not more than Five Hundred Thousand Dollars ($500,000.00), or both.

          (2)  (A)  For marijuana:

                    1.  If thirty (30) grams or less, by imprisonment for not more than three (3) years or a fine of not more than Three Thousand Dollars ($3,000.00), or both;

                    2.  If more than thirty (30) grams but less than two hundred fifty (250) grams, by imprisonment for not more than five (5) years or a fine of not more than Five Thousand Dollars ($5,000.00), or both;

                   3.  If two hundred fifty (250) or more grams but less than five hundred (500) grams, by imprisonment for not less than three (3) years nor more than ten (10) years or a fine of not more than Fifteen Thousand Dollars ($15,000.00), or both;

                   4.  If five hundred (500) or more grams but less than one (1) kilogram, by imprisonment for not less than five (5) years nor more than twenty (20) years or a fine of not more than Twenty Thousand Dollars ($20,000.00), or both.

              (B)  For synthetic cannabinoids:

                   1.  If ten (10) grams or less, by imprisonment for not more than three (3) years or a fine of not more than Three Thousand Dollars ($3,000.00), or both;

                   2.  If more than ten (10) grams but less than twenty (20) grams, by imprisonment for not more than five (5) years or a fine of not more than Five Thousand Dollars ($5,000.00), or both;

                    3.  If twenty (20) or more grams but less than forty (40) grams, by imprisonment for not less than three (3) years nor more than ten (10) years or a fine of not more than Fifteen Thousand Dollars ($15,000.00), or both;

                   4.  If forty (40) or more grams but less than two hundred (200) grams, by imprisonment for not less than five (5) years nor more than twenty (20) years or a fine of not more than Twenty Thousand Dollars ($20,000.00), or both.

          (3)  For controlled substances classified in Schedules III and IV, as set out in Sections 41-29-117 and 41-29-119:

               (A)  If less than two (2) grams or ten (10) dosage units, by imprisonment for not more than five (5) years or a fine of not more than Five Thousand Dollars ($5,000.00), or both;

              (B)  If two (2) or more grams or ten (10) or more dosage units, but less than ten (10) grams or twenty (20) dosage units, by imprisonment for not more than eight (8) years or a fine of not more than Fifty Thousand Dollars ($50,000.00), or both;

              (C)  If ten (10) or more grams or twenty (20) or more dosage units, but less than thirty (30) grams or forty (40) dosage units, by imprisonment for not more than fifteen (15) years or a fine of not more than One Hundred Thousand Dollars ($100,000.00), or both;

              (D)  If thirty (30) or more grams or forty (40) or more dosage units, but less than five hundred (500) grams or two thousand five hundred (2,500) dosage units, by imprisonment for not more than twenty (20) years or a fine of not more than Two Hundred Fifty Thousand Dollars ($250,000.00), or both.

          (4)  For controlled substances classified in Schedule V, as set out in Section 41-29-121:

              (A)  If less than two (2) grams or ten (10) dosage units, by imprisonment for not more than one (1) year or a fine of not more than Five Thousand Dollars ($5,000.00), or both;

               (B)  If two (2) or more grams or ten (10) or more dosage units, but less than ten (10) grams or twenty (20) dosage units, by imprisonment for not more than five (5) years or a fine of not more than Ten Thousand Dollars ($10,000.00), or both;

              (C)  If ten (10) or more grams or twenty (20) or more dosage units, but less than thirty (30) grams or forty (40) dosage units, by imprisonment for not more than ten (10) years or a fine of not more than Twenty Thousand Dollars ($20,000.00), or both;

              (D)  For thirty (30) or more grams or forty (40) or more dosage units, but less than five hundred (500) grams or two thousand five hundred (2,500) dosage units, by imprisonment for not more than fifteen (15) years or a fine of not more than Fifty Thousand Dollars ($50,000.00), or both.

     (c)  Simple possession.  Except as otherwise provided under subsection (i) of this section for actions that are lawful under the Mississippi Medical Cannabis Act and in compliance with rules and regulations adopted thereunder, it is unlawful for any person knowingly or intentionally to possess any controlled substance unless the substance was obtained directly from, or pursuant to, a valid prescription or order of a practitioner while acting in the course of his professional practice, or except as otherwise authorized by this article.  The penalties for any violation of this subsection (c) with respect to a controlled substance classified in Schedules I, II, III, IV or V, as set out in Section 41-29-113, 41-29-115, 41-29-117, 41-29-119 or 41-29-121, including marijuana or synthetic cannabinoids, shall be based on dosage unit as defined herein or the weight of the controlled substance as set forth herein as appropriate:

     "Dosage unit (d.u.)" means a tablet or capsule, or in the case of a liquid solution, one (1) milliliter.  In the case of lysergic acid diethylamide (LSD) the term, "dosage unit" means a stamp, square, dot, microdot, tablet or capsule of a controlled substance.

     For any controlled substance that does not fall within the definition of the term "dosage unit," the penalties shall be based upon the weight of the controlled substance.

     The weight set forth refers to the entire weight of any mixture or substance containing a detectable amount of the controlled substance.

     If a mixture or substance contains more than one (1) controlled substance, the weight of the mixture or substance is assigned to the controlled substance that results in the greater punishment.

      A person shall be charged and sentenced as follows for a violation of this subsection with respect to:

          (1)  A controlled substance classified in Schedule I or II, except marijuana and synthetic cannabinoids:

              (A)  If less than one-tenth (0.1) gram or two (2) dosage units, the violation is a misdemeanor and punishable by imprisonment for not more than one (1) year or a fine of not more than One Thousand Dollars ($1,000.00), or both.

              (B)  If one-tenth (0.1) gram or more or two (2) or more dosage units, but less than two (2) grams or ten (10) dosage units, by imprisonment for not more than three (3) years or a fine of not more than Fifty Thousand Dollars ($50,000.00), or both.

               (C)  If two (2) or more grams or ten (10) or more dosage units, but less than ten (10) grams or twenty (20) dosage units, by imprisonment for not more than eight (8) years or a fine of not more than Two Hundred Fifty Thousand Dollars ($250,000.00), or both.

              (D)  If ten (10) or more grams or twenty (20) or more dosage units, but less than thirty (30) grams or forty (40) dosage units, by imprisonment for not less than three (3) years nor more than twenty (20) years or a fine of not more than Five Hundred Thousand Dollars ($500,000.00), or both.

          (2)  (A)  Marijuana and synthetic cannabinoids:

                   1.  If thirty (30) grams or less of marijuana or ten (10) grams or less of synthetic cannabinoids, by a fine of not less than One Hundred Dollars ($100.00) nor more than Two Hundred Fifty Dollars ($250.00).  The provisions of this paragraph (2)(A) may be enforceable by summons if the offender provides proof of identity satisfactory to the arresting officer and gives written promise to appear in court satisfactory to the arresting officer, as directed by the summons.  A second conviction under this section within two (2) years is a misdemeanor punishable by a fine of Two Hundred Fifty Dollars ($250.00), not more than sixty (60) days in the county jail, and mandatory participation in a drug education program approved by the Division of Alcohol and Drug Abuse of the State Department of Mental Health, unless the court enters a written finding that a drug education program is inappropriate.  A third or subsequent conviction under this paragraph (2)(A) within two (2) years is a misdemeanor punishable by a fine of not less than Two Hundred Fifty Dollars ($250.00) nor more than One Thousand Dollars ($1,000.00) and confinement for not more than six (6) months in the county jail.

     Upon a first or second conviction under this paragraph (2)(A), the courts shall forward a report of the conviction to the Mississippi Bureau of Narcotics which shall make and maintain a private, nonpublic record for a period not to exceed two (2) years from the date of conviction.  The private, nonpublic record shall be solely for the use of the courts in determining the penalties which attach upon conviction under this paragraph (2)(A) and shall not constitute a criminal record for the purpose of private or administrative inquiry and the record of each conviction shall be expunged at the end of the period of two (2) years following the date of such conviction;

                   2.  Additionally, a person who is the operator of a motor vehicle, who possesses on his person or knowingly keeps or allows to be kept in a motor vehicle within the area of the vehicle normally occupied by the driver or passengers, more than one (1) gram, but not more than thirty (30) grams of marijuana or not more than ten (10) grams of synthetic cannabinoids is guilty of a misdemeanor and, upon conviction, may be fined not more than One Thousand Dollars ($1,000.00) or confined for not more than ninety (90) days in the county jail, or both.  For the purposes of this subsection, such area of the vehicle shall not include the trunk of the motor vehicle or the areas not normally occupied by the driver or passengers if the vehicle is not equipped with a trunk.  A utility or glove compartment shall be deemed to be within the area occupied by the driver and passengers.

              (B)  Marijuana:

                   1.  If more than thirty (30) grams but less than two hundred fifty (250) grams, by a fine of not more than One Thousand Dollars ($1,000.00), or confinement in the county jail for not more than one (1) year, or both; or by a fine of not more than Three Thousand Dollars ($3,000.00), or imprisonment in the custody of the Department of Corrections for not more than three (3) years, or both;

                   2.  If two hundred fifty (250) or more grams but less than five hundred (500) grams, by imprisonment for not less than two (2) years nor more than eight (8) years or by a fine of not more than Fifty Thousand Dollars ($50,000.00), or both;

                    3.  If five hundred (500) or more grams but less than one (1) kilogram, by imprisonment for not less than four (4) years nor more than sixteen (16) years or a fine of not more than Two Hundred Fifty Thousand Dollars ($250,000.00), or both;

                   4.  If one (1) kilogram or more but less than five (5) kilograms, by imprisonment for not less than six (6) years nor more than twenty-four (24) years or a fine of not more than Five Hundred Thousand Dollars ($500,000.00), or both;

                   5.  If five (5) kilograms or more, by imprisonment for not less than ten (10) years nor more than thirty (30) years or a fine of not more than One Million Dollars ($1,000,000.00), or both.

              (C)  Synthetic cannabinoids:

                   1.  If more than ten (10) grams but less than twenty (20) grams, by a fine of not more than One Thousand Dollars ($1,000.00), or confinement in the county jail for not more than one (1) year, or both; or by a fine of not more than Three Thousand Dollars ($3,000.00), or imprisonment in the custody of the Department of Corrections for not more than three (3) years, or both;

                   2.  If twenty (20) or more grams but less than forty (40) grams, by imprisonment for not less than two (2) years nor more than eight (8) years or by a fine of not more than Fifty Thousand Dollars ($50,000.00), or both;

                   3.  If forty (40) or more grams but less than two hundred (200) grams, by imprisonment for not less than four (4) years nor more than sixteen (16) years or a fine of not more than Two Hundred Fifty Thousand Dollars ($250,000.00), or both;

                   4.  If two hundred (200) or more grams, by imprisonment for not less than six (6) years nor more than twenty-four (24) years or a fine of not more than Five Hundred Thousand Dollars ($500,000.00), or both.

          (3)  A controlled substance classified in Schedule III, IV or V as set out in Sections 41-29-117 through 41-29-121, upon conviction, may be punished as follows:

              (A)  If less than fifty (50) grams or less than one hundred (100) dosage units, the offense is a misdemeanor and punishable by not more than one (1) year or a fine of not more than One Thousand Dollars ($1,000.00), or both.

              (B)  If fifty (50) or more grams or one hundred (100) or more dosage units, but less than one hundred fifty (150) grams or five hundred (500) dosage units, by imprisonment for not less than one (1) year nor more than four (4) years or a fine of not more than Ten Thousand Dollars ($10,000.00), or both.

              (C)  If one hundred fifty (150) or more grams or five hundred (500) or more dosage units, but less than three hundred (300) grams or one thousand (1,000) dosage units, by imprisonment for not less than two (2) years nor more than eight (8) years or a fine of not more than Fifty Thousand Dollars ($50,000.00), or both.

              (D)  If three hundred (300) or more grams or one thousand (1,000) or more dosage units, but less than five hundred (500) grams or two thousand five hundred (2,500) dosage units, by imprisonment for not less than four (4) years nor more than sixteen (16) years or a fine of not more than Two Hundred Fifty Thousand Dollars ($250,000.00), or both.

     (d)  Paraphernalia.  (1)  Except as otherwise provided under subsection (i) of this section for actions that are lawful under the Mississippi Medical Cannabis Act and in compliance with rules and regulations adopted thereunder, it is unlawful for a person who is not authorized by the State Board of Medical Licensure, State Board of Pharmacy, or other lawful authority to use, or to possess with intent to use, paraphernalia to plant, propagate, cultivate, grow, harvest, manufacture, compound, convert, produce, process, prepare, test, analyze, pack, repack, store, contain, conceal, inject, ingest, inhale or otherwise introduce into the human body a controlled substance in violation of the Uniform Controlled Substances Law.  Any person who violates this subsection (d)(1) is guilty of a misdemeanor and, upon conviction, may be confined in the county jail for not more than six (6) months, or fined not more than Five Hundred Dollars ($500.00), or both; however, no person shall be charged with a violation of this subsection when such person is also charged with the possession of thirty (30) grams or less of marijuana under subsection (c)(2)(A) of this section.

          (2)  It is unlawful for any person to deliver, sell, possess with intent to deliver or sell, or manufacture with intent to deliver or sell, paraphernalia, knowing, or under circumstances where one reasonably should know, that it will be used to plant, propagate, cultivate, grow, harvest, manufacture, compound, convert, produce, process, prepare, test, analyze, pack, repack, store, contain, conceal, inject, ingest, inhale, or otherwise introduce into the human body a controlled substance in violation of the Uniform Controlled Substances Law.  Except as provided in subsection (d)(3), a person who violates this subsection (d)(2) is guilty of a misdemeanor and, upon conviction, may be confined in the county jail for not more than six (6) months, or fined not more than Five Hundred Dollars ($500.00), or both.

          (3)  Any person eighteen (18) years of age or over who violates subsection (d)(2) of this section by delivering or selling paraphernalia to a person under eighteen (18) years of age who is at least three (3) years his junior is guilty of a misdemeanor and, upon conviction, may be confined in the county jail for not more than one (1) year, or fined not more than One Thousand Dollars ($1,000.00), or both.

          (4)  It is unlawful for any person to place in any newspaper, magazine, handbill, or other publication any advertisement, knowing, or under circumstances where one reasonably should know, that the purpose of the advertisement, in whole or in part, is to promote the sale of objects designed or intended for use as paraphernalia.  Any person who violates this subsection is guilty of a misdemeanor and, upon conviction, may be confined in the county jail for not more than six (6) months, or fined not more than Five Hundred Dollars ($500.00), or both.

     (e)  It shall be unlawful for any physician practicing medicine in this state to prescribe, dispense or administer any amphetamine or amphetamine-like anorectics and/or central nervous system stimulants classified in Schedule II, pursuant to Section 41-29-115, for the exclusive treatment of obesity, weight control or weight loss.  Any person who violates this subsection, upon conviction, is guilty of a misdemeanor and may be confined for a period not to exceed six (6) months, or fined not more than One Thousand Dollars ($1,000.00), or both.

     (f)  Trafficking.  (1)  Any person trafficking in controlled substances shall be guilty of a felony and, upon conviction, shall be imprisoned for a term of not less than ten (10) years nor more than forty (40) years and shall be fined not less than Five Thousand Dollars ($5,000.00) nor more than One Million Dollars ($1,000,000.00).  The ten-year mandatory sentence shall not be reduced or suspended.  The person shall not be eligible for probation or parole, the provisions of Sections 41-29-149, 47-5-139, 47-7-3 and 47-7-33, to the contrary notwithstanding.

          (2)  "Trafficking in controlled substances" as used herein means:

               (A)  A violation of subsection (a) of this section involving thirty (30) or more grams or forty (40) or more dosage units of a Schedule I or II controlled substance except marijuana and synthetic cannabinoids;

              (B)  A violation of subsection (a) of this section involving five hundred (500) or more grams or two thousand five hundred (2,500) or more dosage units of a Schedule III, IV or V controlled substance;

               (C)  A violation of subsection (c) of this section involving thirty (30) or more grams or forty (40) or more dosage units of a Schedule I or II controlled substance except marijuana and synthetic cannabinoids;

              (D)  A violation of subsection (c) of this section involving five hundred (500) or more grams or two thousand five hundred (2,500) or more dosage units of a Schedule III, IV or V controlled substance; or

              (E)  A violation of subsection (a) of this section involving one (1) kilogram or more of marijuana or two hundred (200) grams or more of synthetic cannabinoids.

     (g)  Aggravated trafficking.  Any person trafficking in Schedule I or II controlled substances, except marijuana and synthetic cannabinoids, of two hundred (200) grams or more shall be guilty of aggravated trafficking and, upon conviction, shall be sentenced to a term of not less than twenty-five (25) years nor more than life in prison and shall be fined not less than Five Thousand Dollars ($5,000.00) nor more than One Million Dollars ($1,000,000.00).  The twenty-five-year sentence shall be a mandatory sentence and shall not be reduced or suspended.  The person shall not be eligible for probation or parole, the provisions of Sections 41-29-149, 47-5-139, 47-7-3 and 47-7-33, to the contrary notwithstanding.

     (h)  Sentence mitigation.  (1)  Notwithstanding any provision of this section, a person who has been convicted of an offense under this section that requires the judge to impose a prison sentence which cannot be suspended or reduced and is ineligible for probation or parole may, at the discretion of the court, receive a sentence of imprisonment that is no less than twenty-five percent (25%) of the sentence prescribed by the applicable statute.  In considering whether to apply the departure from the sentence prescribed, the court shall conclude that:

              (A)  The offender was not a leader of the criminal enterprise;

              (B)  The offender did not use violence or a weapon during the crime;

              (C)  The offense did not result in a death or serious bodily injury of a person not a party to the criminal enterprise; and

              (D)  The interests of justice are not served by the imposition of the prescribed mandatory sentence.

     The court may also consider whether information and assistance were furnished to a law enforcement agency, or its designee, which, in the opinion of the trial judge, objectively should or would have aided in the arrest or prosecution of others who violate this subsection.  The accused shall have adequate opportunity to develop and make a record of all information and assistance so furnished.

          (2)  If the court reduces the prescribed sentence pursuant to this subsection, it must specify on the record the circumstances warranting the departure.

     (i)  This section does not apply to any of the actions that are lawful under the Mississippi Medical Cannabis Act and in compliance with rules and regulations adopted thereunder.

     SECTION 2.  Section 41-29-113, Mississippi Code of 1972, is brought forward as follows:

     41-29-113.

SCHEDULE I

     (a)  Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, that is listed in this section.

     (b)  Opiates.  Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

          (1)  Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

          (2)  Acetylmethadol;

          (3)  Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

          (4)  Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), also known as acryloylfentanyl;

          (5)  AH-7921 (3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide);

          (6)  Allylprodine;

          (7)  Alphacetylmethadol, except levo-alphacetylmethadol (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

          (8)  Alphameprodine;

          (9)  Alphamethadol;

          (10)  Alpha-Methylfentanyl (N-[1-alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);

          (11)  Alpha-Methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

          (12)  Benzethidine;

          (13)  Betacetylmethadol;

          (14)  Beta-Hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

          (15)  Beta-Hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);

          (16)  Beta-Hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);

          (17)  Betameprodine;

          (18)  Betamethadol;

          (19)  Beta-Methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide), also known as β-methyl fentanyl;

          (20)  Beta'-Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide), also known as β'-phenyl fentanyl or 3-phenylpropanoyl fentanyl;

          (21)  Betaprodine;

          (22)  Butyrl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

          (23)  Clonitazene;

          (24)  Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);

          (25)  Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

          (26)  Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

          (27)  Dextromoramide;

          (28)  Diampromide;

          (29)  Diethylthiambutene;

          (30)  Difenoxin;

          (31)  Dimenoxadol;

          (32)  Dimepheptanol;

          (33)  Dimethylthiambutene;

          (34)  Dioxaphetyl butyrate;

          (35)  Dipipanone;

          (36)  Ethylmethylthiambutene;

          (37)  Etonitazene;

          (38)  Etoxeridine;

          (39)  Fentanyl carbamate (ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate);

          (40)  Fentanyl-related substances, meaning any substance not otherwise listed under another schedule and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is structurally related to fentanyl by one or more of the following modifications:

              (A)  Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

               (B)  Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;

              (C)  Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;

              (D)  Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or

              (E)  Replacement of the N-propionyl group by another acyl group.

          (41)  4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide), also known as para-fluoroisobutyryl fentanyl);

          (42)  2'-Fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)

propionamide), also known as 2'-fluoro 2-fluorofentanyl;

          (43)  Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

          (44)  Furethidine;

          (45)  Hydroxypethidine;

          (46)  Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

          (47)  Isotonitazene (N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);

          (48)  Ketobemidone (including the optical and geometric isomers);

          (49)  Levomoramide;

          (50)  Levophenacylmorphan;

          (51)  Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

          (52)  4'-Methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);

          (53)  3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);

          (54)  3-Methylthiofentanyl (N-[3-methyl-1-

(2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide);

          (55)  Morpheridine;

          (56)  MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

          (57)  MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);

          (58)  Noracymethadol;

          (59)  Norlevorphanol;

          (60)  Normethadone;

          (61)  Norpipanone;

          (62)  Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-

(1-phenethylpiperidin-4-yl)acetamide);

          (63)  Ortho-Fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);

          (64)  Ortho-Fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide), also known as 2-fluorobutyryl fentanyl;

          (65)  Ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide), also known as 2-fluorofentanyl;

          (66)  Ortho-Fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

          (67)  Ortho-Methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide), also known as 2-methyl acetylfentanyl;

          (68)  Ortho-Methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)

acetamide), also known as 2-methyl methoxyacetyl fentanyl;

          (69)  Para-Chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

          (70)  Para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

          (71)  Para-Fluorofentanyl (N-(4-fluorophenyl)

-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide);

          (72)  Para-Fluoro furanyl fentanyl N-(4-fluorophenyl)-N-

(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

          (73)  Para-Methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

          (74)  Para-Methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide), also known as 4-methylfentanyl);

          (75)  PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);

          (76)  Phenadoxone;

          (77)  Phenampromide;

          (78)  Phenomorphan;

          (79)  Phenoperidine;

          (80)  Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide), also known as benzoyl fentanyl;

          (81)  Piritramide;

          (82)  Proheptazine;

          (83)  Properidine;

          (84)  Propiram;

          (85)  Racemoramide;

          (86)  Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-

carboxamide);

          (87)  Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);

          (88)  Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide), also known as 2-thiofuranyl fentanyl or thiophene fentanyl;

          (89)  Tilidine;

          (90)  Trimeperidine;

          (91)  U-47700, (3,4-dichloro-N-

[2-(dimethylamino)cyclohexyl]-N-methylbenzamide);

          (92)  Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide).

     (c)  Opium derivatives.  Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

          (1)  Acetorphine;

          (2)  Acetyldihydrocodeine;

          (3)  Benzylmorphine;

          (4)  Codeine methylbromide;

          (5)  Codeine-N-Oxide;

          (6)  Cyprenorphine;

          (7)  Desomorphine;

          (8)  Dihydromorphine;

          (9)  Drotebanol;

          (10)  Etorphine (except hydrochloride salt);

          (11)  Heroin;

          (12)  Hydromorphinol;

          (13)  Methyldesorphine;

          (14)  Methyldihydromorphine;

          (15)  Monoacetylmorphine;

          (16)  Morphine methylbromide;

          (17)  Morphine methylsulfonate;

          (18)  Morphine-N-Oxide;

          (19)  Myrophine;

          (20)  Nicocodeine;

          (21)  Nicomorphine;

          (22)  Normorphine;

          (23)  Pholcodine;

          (24)  Thebacon.

     (d)  Hallucinogenic substances.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric) and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

          (1)  Alpha-ethyltryptamine;

          (2)  4-bromo-2,5-dimethoxy-amphetamine;

          (3)  4-bromo-2,5-dimethoxyphenethylamine;

          (4)  2,5-dimethoxyamphetamine;

          (5)  2,5-dimethoxy-4-ethylamphetamine (DOET);

          (6)  2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);

          (7)  4-methoxyamphetamine;

          (8)  5-methoxy-3,4-methylenedioxy-amphetamine;

          (9)  4-methyl-2,5-dimethoxy-amphetamine;

          (10)  3,4-methylenedioxy amphetamine;

          (11)  3,4-methylenedioxymethamphetamine (MDMA);

          (12)  3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);

          (13)  N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy MDA, N-OHMDA, and N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);

          (14)  3,4,5-trimethoxy amphetamine;

          (15)  5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

          (16)  Alpha-methyltryptamine (also known as AMT);

          (17)  Bufotenine;

          (18)  Diethyltryptamine;

          (19)  Dimethyltryptamine;

          (20)  5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

          (21)  Ibogaine;

          (22)  Lysergic acid diethylamide (LSD);

          (23)  (A)  Marijuana (Hemp as defined and regulated under Sections 69-25-201 through 69-25-221 and Cannabidiol contained in a legend drug product approved by the Federal Food and Drug Administration or obtained under Section 41-29-136 are exempt under Schedule I);

              (B)  Hashish;

          (24)  Mescaline;

          (25)  Parahexyl;

          (26)  Peyote;

          (27)  N-ethyl-3-piperidyl benzilate;

          (28)  N-methyl-3-piperidyl benzilate;

          (29)  Psilocybin;

          (30)  Psilocyn;

          (31)  Tetrahydrocannabinols, meaning tetrahydrocannabinols contained in a plant of the genus Cannabis (cannabis plant), as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant such as the following:

              (A)  1 cis or trans tetrahydrocannabinol;

               (B)  6 cis or trans tetrahydrocannabinol;

              (C)  3,4 cis or trans tetrahydrocannabinol.

     (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of atomic positions, are covered.)

     ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)  For purposes of this paragraph, tetrahydrocannabinols do not include hemp or hemp products regulated under Sections 69-25-201 through 69-25-221.

     However, the following products are exempted from control:

                   (i)  THC-containing industrial products made from cannabis stalks (e.g., paper, rope and clothing);

                   (ii)  Processed cannabis plant materials used for industrial purposes, such as fiber retted from cannabis stalks for use in manufacturing textiles or rope;

                   (iii)  Animal feed mixtures that contain sterilized cannabis seeds and other ingredients (not derived from the cannabis plant) in a formula designed, marketed and distributed for nonhuman consumption;

                   (iv)  Personal care products that contain oil from sterilized cannabis seeds, such as shampoos, soaps, and body lotions (if the products do not cause THC to enter the human body);

                   (v)  Hemp as regulated under Sections 69-25-201 through 69-25-221; and

                   (vi)  Any product derived from the hemp plant designed for human ingestion and/or consumption that is approved by the United States Food and Drug Administration;

          (32)  Phencyclidine;

          (33)  Ethylamine analog of phencyclidine (PCE);

          (34)  Pyrrolidine analog of phencyclidine (PHP, PCPy);

          (35)  Thiophene analog of phencyclidine;

          (36)  1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);

          (37)  4-methylmethcathinone (mephedrone);

          (38)  3,4-methylenedioxypyrovalerone (MDPV);

          (39)  2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);

          (40)  2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);

          (41)  2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

          (42)  2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); or 2,5-dimethoxy-4-iodophenethylamine;

          (43)  2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

          (44)  2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

          (45)  2-(2,5-dimethoxyphenyl)ethanamine (2C-H);

          (46)  2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

          (47)  2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

          (48)  3,4-methylenedioxy-N-methylcathinone(methylone);

          (49)  2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);

          (50)  2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);

          (51)  2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);

          (52)  7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1, 4-benzodiazepin-2-one (also known as Phenazepam);

          (53)  7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8, 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene (also known as Etizolam);

          (54)  Salvia divinorum;

          (55)  Synthetic cannabinoids.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found in any of the following chemical groups, whether or not substituted to any extent, or any of those groups which contain any synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic cannabinoid chemical analogues in such groups:

              (A)  (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol (also known as HU-210 or 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

              (B)  Naphthoylindoles and naphthylmethylindoles, being any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted in the indole ring to any extent, or in the naphthyl ring to any extent;

              (C)  Naphthoylpyrroles, being any compound structurally derived from 3-(1-naphthoyl)pyrrole, whether or not substituted in the pyrrole ring to any extent, or in the naphthyl ring to any extent;

              (D)  Naphthylmethylindenes, being any compound structurally derived from 1-(1-naphthylmethyl)indene, whether or not substituted in the indene ring to any extent or in the naphthyl ring to any extent;

              (E)  Phenylacetylindoles, being any compound structurally derived from 3-phenylacetylindole, whether or not substituted in the indole ring to any extent or in the phenyl ring to any extent;

              (F)  Cyclohexylphenols, being any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether or not substituted in the cyclohexyl ring to any extent or in the phenolic ring to any extent;

              (G)  Benzoylindoles, whether or not substituted in the indole ring to any extent or in the phenyl ring to any extent;

              (H)  Adamantoylindoles, whether or not substituted in the indole ring to any extent or in the adamantoyl ring system to any extent;

              (I)  Tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, except where contained in cannabis or cannabis resin;

              (J)  3-Cyclopropylmethanone indole or 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl rings to any extent;

              (K)  Quinolinyl ester indoles, being any compound structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;

              (L)  3-carboxamide-1H-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen;

              (M)  Cycloalkanemethanone Indoles, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cycloalkane ring to any extent;

          (56)  Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, also known as NM2201 or CBL2201;

          (57)  1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- pyrrolo[2,3-b]pyridine-3-carboxamide, also known as 5F-CUMYL-P7AICA or SGT-25;

          (58)  Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, also known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA)

          (59)  1-(4-methoxyphenyl)-N-methylpropan-2-amine, also known as para-methoxymethamphetamine or PMMA

          (60)  Ethyl 2-(1-(5-fluoropentyl) -1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, also known as 5F-EDMB-PINACA;

          (61)  Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate, also known as 5F-MDMB-PICA or 5F-MDMB-2201;

          (62)  N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, also known as FUB-AKB48 or FUB-APINACA or AKB48 N-(4-fluorobenzyl);

          (63)  (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, also known as FUB-144;

          (64)  N-ethylhexedrone, also known as α-ethylaminohexanophenone or 2-(ethylamino)-1-phenylhexan-1-one;

          (65)  Alpha-pyrrolidinohexanophenone, also known as α-PHP or α-pyrrolidinohexanophenone or 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);

          (66)  4-methyl-alpha-ethylaminopentiophenone, also known as 4-MEAP or 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);

          (67)  4′-methyl-alpha-pyrrolidinohexiophenone, also known as MPHP or 4′-methyl-alpha-pyrrolidinohexanophenone or 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);

          (68)  Alpha-pyrrolidinoheptaphenone (also known as PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);

          (69)  4′-chloro-alpha-pyrrolidinovalerophenone, also known as 4-chloro-α-PVP or 4′-chloro-α-pyrrolidinopentiophenone or 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);

          (70)  2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one, also known as methoxetamine or MXE.

     (e)  Depressants.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

          (1)  Clonazolam,

6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine;

          (2)  Flualprazolam,

8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine;

          (3)  Flubromazepam,

7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;

          (4)  Flubromazolam,

8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin;

          (5)  Gamma-hydroxybutyric acid (other names include:  GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

          (6)  Mecloqualone;

          (7)  Methaqualone.

     (f)  Stimulants.  Any material, compound, mixture or preparation which contains any quantity of the following central nervous system stimulants including optical salts, isomers and salts of isomers unless specifically excepted or unless listed in another schedule:

          (1)  Aminorex;

          (2)  N-benzylpiperazine (also known as BZP and 1-benzylpiperazine);

          (3)  Cathinone;

          (4)  4,4′-Dimethylaminorex, also known as 4,4′-DMAR or 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);

          (5)  Fenethylline;

          (6)  Methcathinone;

          (7)  4-methylaminorex (also known as 2-amino-4-methyl-5-phenyl-2-oxazoline);

          (8)  N-ethylamphetamine;

          (9)  Any material, compound, mixture or preparation which contains any quantity of N,N-dimethylamphetamine.  (Other names include:  N,N,-alpha-trimethyl-benzeneethanamine and N,N-alpha-trimethylphenethylamine);

          (10)  Synthetic cathinones.  (A)  Unless listed in another schedule, any compound other than bupropion that is structurally derived from 2-Amino-1-phenyl-1-propanone by modification in any of the following ways:

                   (i)  By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

                   (ii)  By substitution at the 3-position with an alkyl substituent;

                   (iii)  By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

              (B)  The compounds covered in this paragraph (10) include, but are not limited to, any material, compound, mixture or preparation which contains any quantity of a synthetic cathinone found in any of the following compounds, whether or not substituted to any extent, or any of these compounds which contain any synthetic cathinone, or salts, isomers, or salts of isomers, whenever the existence of such salts, isomers or salts of isomers is possible, unless specifically excepted or listed in another schedule:

                   (i)  4-methyl-N-ethylcathinone ("4-MEC");

                   (ii)  4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP");

                   (iii)  Alpha-pyrrolidinopentiophenone ("α-PVP");

                   (iv)  1-(1,3-benzodioxol-5-yl)-2- (methylamino)butan-1-one ("butylone");

                   (v)  2-(methylamino)-1-phenylpentan-1-one ("pentedrone");

                   (vi)  1-(1,3-benzodioxol-5-yl)-2- (methylamino)pentan-1-one ("pentylone");

                   (vii)  4-fluoro-N-methylcathinone ("4-FMC");

                   (viii)  3-fluoro-N-methylcathinone ("3-FMC");

                   (ix)  1-(naphthalen-2-yl)-2- (pyrrolidin-1-yl) pentan-1-one ("naphyrone");

                   (x)  Alpha-pyrrolidinobutiophenone ("α-PBP"); and

                   (xi)  1-(1,3-benzodioxol-5-yl)-2-(ethylamino) -pentan-1-one (N-ethylpentylone, ephylone).

     SECTION 3.  Section 41-29-115, Mississippi Code of 1972, is brought forward as follows:

     41-29-115.  (a)  The controlled substances listed in this section, by whatever official name, common or usual name, chemical name, or brand name designated, are included in Schedule II.

SCHEDULE II

     (b)  Substances, vegetable origin or chemical synthesis.  Unless specifically excepted or unless listed in other schedules, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

          (1)  Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone and naltrexone, but including the following:

              (i)  Codeine;

              (ii)  Dihydroetorphine;

               (iii)  Ethylmorphine;

              (iv)  Etorphine hydrochloride;

              (v)  Granulated opium;

              (vi)  Hydrocodone, whether alone or in combination with any material, compound, mixture or preparation;

              (vii)  Hydromorphone;

              (viii)  Metopon;

              (ix)  Morphine;

               (x)  Opium extracts;

              (xi)  Opium fluid extracts;

              (xii)  Oripavine;

              (xiii)  Oxycodone;

              (xiv)  Oxymorphone;

              (xv)  Powdered opium;

              (xvi)  Raw opium;

              (xvii)  Thebaine;

              (xviii)  Tincture of opium;

          (2)  Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium;

          (3)  Opium poppy and poppy straw;

          (4)  Coca leaves and any salt, compound, derivative, or preparation of cocaine or coca leaves, including cocaine and ecgonine and any salt, compound, derivative, isomer, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including:

               (i)  Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; or

              (ii)  Ioflupane;

          (5)  Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy).

     (c)  Opiates.  Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within the specified chemical designation, dextrorphan and levopropoxyphene excepted:

          (1)  Alfentanil;

          (2)  Alphaprodine;

          (3)  Anileridine;

          (4)  Bezitramide;

          (5)  Bulk dextropropoxyphene (nondosage forms);

          (6)  Carfentanil;

          (7)  Dihydrocodeine;

          (8)  Diphenoxylate;

          (9)  Fentanyl;

          (10)  Isomethadone;

          (11)  Levo-alphacetylmethadol (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM);

          (12)  Levomethorphan;

          (13)  Levorphanol;

          (14)  Metazocine;

          (15)  Methadone;

          (16)  Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane;

          (17)  Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;

          (18)  Oliceridine (N-[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-

oxaspiro[4.5]decan-9-yl]ethyl})amine);

          (19)  Pethidine (meperidine);

          (20)  Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

          (21)  Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;

          (22)  Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

          (23)  Phenazocine;

          (24)  Piminodine;

          (25)  Racemethorphan;

          (26)  Racemorphan;

          (27)  Remifentanil;

          (28)  Sufentanil;

          (29)  Tapentadol;

          (30)  Thiafentanil, methyl 4-(2-methoxy-N-phenylacetamido)-1-(2-(thiophen-2-yl)ethyl)

piperidine-4-carboxylate).

     (d)  Stimulants.  Any material, compound, mixture, or preparation which contains any quantity of the following substances:

          (1)  Amphetamine, its salts, optical isomers, and salts of its optical isomers;

          (2)  Phenmetrazine and its salts;

          (3)  Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;

          (4)  Methylphenidate and its salts;

          (5)  Lisdexamfetamine, its salts, isomers and salts of isomers.

     (e)  Depressants.  Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

          (1)  Amobarbital;

          (2)  Secobarbital;

          (3)  Pentobarbital;

          (4)  Glutethimide.

     (f)  Hallucinogenic substances.

          (1)  Dronabinol oral solution [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)];

          (2)  Nabilone [other names include:  (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

     (g)  Immediate precursors.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

          (1)  Amphetamine and methamphetamine immediate precursor:  Phenylacetone (other names include:  phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone);

          (2)  Phencyclidine immediate precursors:

              (i)  1-phenylcyclohexylamine;

               (ii)  1-piperidinocyclohexanecarbonitrile (PCC);

          (3)  Fentanyl immediate precursor:  4-anilino-N-phenethyl-4-piperidine (ANPP).

     (h)  Any material, compound, mixture or preparation which contains any quantity of a Schedule II controlled substance and is listed as an exempt substance in 21 CFR, Section 1308.24 or 1308.32, shall be exempted from the provisions of the Uniform Controlled Substances Law.

     SECTION 4.  Section 41-29-117, Mississippi Code of 1972, is brought forward as follows:

     41-29-117.  (A)  The controlled substances listed in this section are included in Schedule III.

SCHEDULE III

          (a)  Stimulants.  Any material, compound, mixture, or preparation which contains any quantity of the following substances or their salts, isomers, or salts of isomers, of the following substances:

              (1)  Benzphetamine;

              (2)  Chlorphentermine;

              (3)  Clortermine;

              (4)  Phendimetrazine.

          (b)  Depressants.  Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

              (1)  Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;

              (2)  Unless specifically excepted or unless listed in another schedule, any compound, mixture or preparation containing any of the following substances or any salt of the substances specifically included in this subsection (2) and one or more other active medicinal ingredients which are not listed in any other schedule:

                   (i)  Amobarbital;

                   (ii)  Secobarbital;

                   (iii)  Pentobarbital;

              (3)  Any suppository dosage form containing any of the following substances or any salt of any of the substances specifically included in this subsection (3) approved by the Food and Drug Administration for marketing only as a suppository:

                   (i)  Amobarbital;

                   (ii)  Secobarbital;

                   (iii)  Pentobarbital;

              (4)  Chlorhexadol;

              (5)  Embutramide;

              (6)  Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug and Cosmetic Act;

              (7)  Ketamine; its salts, isomers, and salts of isomers; other names include (+)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone;

              (8)  Lysergic acid;

               (9)  Lysergic acid amide;

              (10)  Methyprylon;

              (11)  Perampanel; its salts, isomers, and salts of isomers;

              (12)  Sulfondiethylmethane;

              (13)  Sulfonethylmethane;

              (14)  Sulfonmethane;

              (15)  Tiletamine and zolazepam or any salt thereof; other names for the tiletamine and zolazepam combination product include:  telazol; other names for tiletamine include: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; other names for zolazepam include:  4-(2-fluorophenyl)-6,8-dihydro 1,3, 8-trimethylpyrazolo-[3,4-e](1,4)-diazepin-7(1H)-one, flupyrazapon.

          (c)  Nalorphine.

          (d)  Any material, compound, mixture or preparation which contains any quantity of ephedrine or pseudoephedrine, except for any product that contains any quantity of pseudoephedrine or ephedrine that is sold subject to the quantity restrictions authorized in Section 73-21-124.

          (e)  Narcotic drugs.  Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

              (1)  Not more than one and eight-tenths (1.8) grams of codeine, or any of its salts, per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

               (2)  Not more than one and eight-tenths (1.8) grams of codeine, or any of its salts, per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

              (3)  Not more than one and eight-tenths (1.8) grams of dihydrocodeine, or any of its salts, per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

              (4)  Not more than three hundred (300) milligrams of ethylmorphine, or any of its salts, per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

              (5)  Not more than five hundred (500) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams, or not more than twenty-five (25) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

              (6)  Not more than fifty (50) milligrams of morphine, or any of its salts, per one hundred (100) milliliters or per one hundred (100) grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

          (f)  Anabolic steroids.  Unless specifically exempted or listed in another schedule, any material, compound, mixture or preparation containing any quantity of any of the following anabolic steroids (any drug or hormonal substance chemically and pharmacologically related to testosterone other than estrogens, progestins, corticosteroids and dehydroepiandrosterone):

              (1)  3beta,17-dihydroxy-5a-androstane;

               (2)  3alpha,17beta-dihydroxy-5a-androstane;

              (3)  5alpha-androstan-3,17-dione;

              (4)  1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);

              (5)  1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);

              (6)  4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);

              (7)  5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);

              (8)  1-androstenedione ([5alpha]-androst-1-en-3, 17-dione);

              (9)  4-androstenedione (androst-4-en-3,17-dione);

              (10)  5-androstenedione (androst-5-en-3,17-dione);

              (11)  Bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);

              (12)  Boldenone (17beta-hydroxyandrost-1,4,-diene-3-one);

               (13)  Boldione (androsta-1,4-diene-3,17-dione);

              (14)  Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);

              (15)  Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one);

              (16)  Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);

              (17)  Desoxymethyltestosterone (17alpha-methyl-5alpha-androst-2-en-17beta-ol, also known as madol);

              (18)  Delta1-dihydrotestosterone (also known as 1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);

              (19)  4-dihydrotestosterone (17beta-hydroxy-androstan-3-one);

              (20)  Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);

              (21)  Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);

              (22)  Fluoxymesterone (9-fluoro-17alpha-methyl-11beta, 17beta-dihydroxyandrost-4-en-3-one);

              (23)  Formebolone (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1, 4-dien-3-one);

              (24)  Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);

              (25)  13beta-ethyl-17alpha-hydroxygon-4-en-3-one;

              (26)  4-hydroxytestosterone (4,17beta-dihydroxyandrost-4-en-3-one);

              (27)  4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);

              (28)  Mestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);

              (29)  Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);

               (30)  Methandienone (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);

               (31)  Methandriol (17alpha-methyl-3beta, 17beta-dihydroxyandrost-5-ene);

              (32)  Methasterone (2[alpha], 17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one;

              (33)  Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);

              (34)  17alpha-methyl-3beta, 17beta-dihydroxy-5a-androstane;

              (35)  17alpha-methyl-3alpha, 17beta-dihydroxy-5a-androstane;

              (36)  17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;

              (37)  17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);

              (38)  Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);

              (39)  Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);

              (40)  Methyltestosterone (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);

              (41)  Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);

              (42) 17alpha-methyl-Delta1-dihydrotestosterone (17b beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (also known as 17-alpha-methyl-1-testosterone);

              (43)  Nandrolone (17beta-hydroxyestr-4-en-3-one);

              (44)  19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);

              (45)  19-nor-4-androstenediol (3a,17beta-dihydroxyestr-4-ene);

              (46)  19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);

              (47)  19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);

              (48)  19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene3,17-dione, 19-norandrosta-4,9(10)-diene-3,17-dione);

              (49)  19-nor-4-androstenedione (estr-4-en-3,17-dione);

              (50)  19-nor-5-androstenedione (estr-5-en-3,17-dione);

              (51)  Norbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);

              (52)  Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);

              (53)  Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);

               (54)  Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);

              (55)  Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);

              (56)  Oxymesterone (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);

              (57)  Oxymetholone (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]- androstan-3-one);

              (58)  Prostanozol

(17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pyrazole)

              (59)  Stanozolol (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]­- pyrazole);

              (60)  Stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);

              (61)  Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

              (62)  Testosterone (17beta-hydroxyandrost-4-en-3-one);

              (63)  Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);

              (64)  Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one);

              (65)  Any salt, ester, or ether of a drug or substance described in this paragraph.  Except such term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration.  If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph.

          (g)  Any material, compound, mixture or preparation which contains any quantity of buprenorphine or its salts.

          (h)  Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product.

          (i)  Any material, compound, mixture, or preparation which contains any quantity of Tianeptine (7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid) or its salts, isomers, salts of isomers, sulfate, free acid or derivative thereof.

     (B)  Any material, compound, mixture or preparation which contains any quantity of a Schedule III controlled substance other than butalbital, and is listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions of the Uniform Controlled Substances Law.

     SECTION 5.  Section 41-29-119, Mississippi Code of 1972, is brought forward as follows:

     41-29-119.  (A)  The controlled substances listed in this section are included in Schedule IV.

                          SCHEDULE IV

          (a)  Narcotic drugs.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains limited quantities of the following narcotic drugs, or any salts thereof:

               (1)  Not more than one (1) milligram of difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;

              (2)  Dextropropoxyphene, including its salts (Darvon, Darvon-N; also found in Darvon compound and Darvocet-N, etc.);

               (3)  2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol).

          (b)  Depressants.  Any material, compound, mixture or preparation which contains any quantity of the following substances:

              (1)  Alfaxalone;

              (2)  Alprazolam;

              (3)  Barbital;

              (4)  Brexanolone;

              (5)  Bromazepam;

              (6)  Camazepam;

              (7)  Carisoprodol;

              (8)  Chloral betaine;

              (9)  Chloral hydrate;

              (10)  Chlordiazepoxide and its salts, but does not include chlordiazepoxide hydrochloride and clidinium bromide or chlordiazepoxide and esterified estrogens;

              (11)  Clobazam;

              (12)  Clonazepam;

               (13)  Clorazepate;

              (14)  Clotiazepam;

              (15)  Cloxazolam;

               (16)  Delorazepam;

              (17)  Diazepam;

              (18)  Dichloralphenazone;

              (19)  Estazolam;

              (20)  Ethchlorvynol;

              (21)  Ethinamate;

              (22)  Ethyl loflazepate;

              (23)  Fludiazepam;

              (24)  Flunitrazepam;

              (25)  Flurazepam;

               (26)  Fospropofol;

              (27)  Halazepam;

               (28)  Haloxazolam;

              (29)  Ketazolam;

               (30)  Lemborexant;

              (31)  Loprazolam;

              (32)  Lorazepam;

               (33)  Lormetazepam;

              (34)  Mebutamate;

              (35)  Medazepam;

              (36)  Meprobamate;

              (37)  Methohexital;

              (38)  Methylphenobarbital;

              (39)  Midazolam;

              (40)  Nimetazepam;

              (41)  Nitrazepam;

              (42)  Nordiazepam;

              (43)  Oxazepam;

              (44)  Oxazolam;

              (45)  Paraldehyde;

              (46)  Petrichloral;

              (47)  Phenobarbital;

              (48)  Pinazepam;

              (49)  Prazepam;

              (50)  Quazepam;

              (51)  Remimazolam;

               (52)  Suvorexant;

              (53)  Temazepam;

              (54)  Tetrazepam;

              (55)  Triazolam;

              (56)  Zaleplon;

              (57)  Zolpidem;

              (58)  Zopiclone.

          (c)  Fenfluramine.

          (d)  Lorcaserin.  Any material, compound, mixture, or preparation which contains any quantity of Lorcaserin, including its salts, isomers, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible.

          (e)  Stimulants.  Any material, compound, mixture or preparation which contains any quantity of the following substances:

              (1)  Cathine ((+/-) Norpseudoephedrine);

              (2)  Diethylpropion;

              (3)  Fencamfamin;

              (4)  Fenproporex;

              (5)  Mazindol;

              (6)  Mefenorex;

              (7)  Modafinil;

              (8)  Pemoline (including any organometallic complexes and chelates thereof);

              (9)  Phentermine;

              (10)  Pipradrol;

              (11)  Serdexmethylphenidate;

               (12)  Sibutramine;

              (13)  Solriamfetol;

              (14)  SPA ((-)-1-dimethylamino-1,2-diphenylethane).

          (f)  Other substances.

              (1)  Pentazocine;

              (2)  Butorphanol (including its optical isomers);

               (3)  Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid); (including its optical isomers) and its salts, isomers, and salts of isomers.

     (B)  Any material, compound, mixture or preparation which contains any quantity of a Schedule IV controlled substance and is listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions of the Uniform Controlled Substances Law.

     SECTION 6.  Section 41-29-121, Mississippi Code of 1972, is brought forward as follows:

     41-29-121.

SCHEDULE V

     (a)  Schedule V consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

     (b)  Narcotic drugs.  [Reserved]

     (c)  Narcotic drugs containing nonnarcotic active medicinal ingredients.  Any compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

          (1)  Not more than two hundred (200) milligrams of codeine, or any of its salts, per one hundred (100) milliliters or per one hundred (100) grams;

          (2)  Not more than one hundred (100) milligrams of dihydrocodeine, or any of its salts, per one hundred (100) milliliters or per one hundred (100) grams;

          (3)  Not more than one hundred (100) milligrams of ethylmorphine, or any of its salts, per one hundred (100) milliliters or per one hundred (100) grams;

          (4)  Not more than two and five-tenths (2.5) milligrams of diphenoxylate and not less than twenty-five (25) micrograms of atropine sulphate per dosage unit;

          (5)  Not more than one hundred (100) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams;

          (6)  Not more than five-tenths (0.5) milligram of difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit.

     (d)  Stimulants.  Unless specifically excepted or listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers and salts of isomers:  Pyrovalerone.

     (e)  Depressants.  Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers:

          (1)  Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact);

          (2)  Cenobamate ([(1R)-1-2-chlorophenyl)-2-tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)

-2-(2H-tetrazol-2-yl)ethyl ester);

          (3)  Ezogabine [N-[2-amino-4-(4-

fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];

          (4)  Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];

          (5)  Lasmiditan [2,4,6-trifluoro-N-(6-

(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide];

          (6)  Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

     (f)  Any material, compound, mixture or preparation which contains any quantity of a Schedule V controlled substance and is listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions of the Uniform Controlled Substances Law.

     SECTION 7.  This act shall take effect and be in force from and after July 1, 2024.